Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia

BACKGROUND: Eltrombopag (EPAG), an oral thrombopoietin receptor agonist (TPO-RA), has been proven to improve the hematologic response without increasing toxic effects as a first-line therapy combined with standard immunosuppressive treatment (IST) in adults with severe aplastic anemia (SAA). Neverth...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yufei, Yang, Wenrui, Zhao, Xin, Hu, Xiangrong, Hu, Jing, Liu, Xu, Li, Jianping, Ye, Lei, Xiong, Youzhen, Yang, Yang, Zhang, Baohang, Li, Xiaoxia, Yang, Xiawan, Shi, Yimeng, Peng, Guangxin, Li, Yuan, Fan, Huihui, Zhou, Kang, Jing, Liping, Zhang, Li, Zhang, Fengkui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872003/
https://www.ncbi.nlm.nih.gov/pubmed/36704148
http://dx.doi.org/10.3389/fped.2022.1095143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872003/
https://www.ncbi.nlm.nih.gov/pubmed/36704148
http://dx.doi.org/10.3389/fped.2022.1095143

Ejemplares similares